Who is sponsoring NCT07208526?

NCT07208526 is sponsored by Shanghai Zhongshan Hospital.

What drugs are being tested in NCT07208526?

Interventions in NCT07208526: GOLP regimen, Surgery, TDTP-RECIST.

What condition does NCT07208526 study?

NCT07208526 studies Intrahepatic Cholangiocarcinoma (Icc), Conversion Therapy, TDTP-RECIST, GOLP Regimen.

Is NCT07208526 still recruiting?

NCT07208526 is currently not yet recruiting. Last updated 6 October 2025.

Last reviewed 2025-10-06 · How we verify

NCT07208526

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized Trial of Surgical Decision-Making Guided by TDTP-RECIST

Not yet recruiting NA Last updated 6 October 2025

What this trial tests

NA trial testing GOLP regimen in Intrahepatic Cholangiocarcinoma (Icc) in 270 participants. Not yet recruiting.

Timeline

1 December 2025

Primary endpoint
30 June 2028

31 December 2028

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	270
Start date	1 December 2025
Primary completion	30 June 2028
Estimated completion	31 December 2028
Sites	1 location across China

Drugs / interventions tested

GOLP regimen — full drug profile →
Surgery
TDTP-RECIST

Conditions studied

Intrahepatic Cholangiocarcinoma (Icc) — all drugs for Intrahepatic Cholangiocarcinoma (Icc) →
Conversion Therapy — all drugs for Conversion Therapy →
TDTP-RECIST — all drugs for TDTP-RECIST →
GOLP Regimen — all drugs for GOLP Regimen →

Sponsor

Shanghai Zhongshan Hospital

Who can join

Adults 18 to 75, any sex, with Intrahepatic Cholangiocarcinoma (Icc) or Conversion Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project aims to conduct a prospective, multicenter, randomized controlled clinical trial. The study plans to enroll 270 patients with locally advanced iCCA who have successfully undergone GOLP conversion therapy. Participants will be randomized at a 1:2:2 ratio into three arms: Control Arm (continued medication), Direct Surgery Arm, and TDTP-RECIST Assessment Arm. The primary endpoint is Overall Survival (OS).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Intrahepatic Cholangiocarcinoma (Icc)

Currently open trials in the same condition.

NCT06735560 — Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN · NA · recruiting
NCT07070700 — Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Chol · Phase 2 · recruiting
NCT07063888 — A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcin · Phase 2 · recruiting
NCT06862934 — Liver Transplantation for Unresectable Intrahepatic Colangiocarcinoma After Sustained Response to Neoadjuvant Treatments · recruiting
NCT06859684 — Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced · Phase 2 · recruiting

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07208526 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 6 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07208526.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing